Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease.

ABSTRACT:

Background

Intraputamenal glial cell line-derived neurotrophic factor (GDNF), administered every 4 weeks to patients with moderately advanced Parkinson's disease, did not show significant clinical improvements against placebo at 40 weeks, although it significantly increased [18F]DOPA uptake throughout the entire putamen.

Objective

This open-label extension study explored the effects of continued (prior GDNF patients) or new (prior placebo patients) exposure to GDNF for another 40 weeks.

Methods

Using the infusion protocol of the parent study, all patients received GDNF without disclosing prior treatment allocations (GDNF or placebo). The primary outcome was the percentage change from baseline to Week 80 in the OFF state Unified Parkinson's Disease Rating Scale (UPDRS)

SUBMITTER: Whone AL 

PROVIDER: S-EPMC6597995 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature